Sir, Ertapenem is a b-lactam that is recommended for the treatment of community-acquired intra-abdominal peritonitis. 1 Its activity includes extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae, which are increasingly being identified in the community. 2 In critically ill patients, physiological alterations may affect the pharmacokinetic parameters of antimicrobial agents and, consequently, their effectiveness and/or the risk of selecting resistant strains when underdosing. 3, 4 The purpose of this study was to determine the plasma and peritoneal concentrations of ertapenem in patients requiring intensive care for secondary peritonitis.
Nine adult patients, hospitalized in the intensive care unit (ICU), suffering from severe secondary peritonitis that required surgical treatment and at least one peritoneal drainage were eligible. Exclusion criteria were pregnant women, and/or patients known to have an allergy to carbapenems and/or those who had creatinine clearance (CL CR ) of ,30 mL/min (CockcroftGault formula 5 ). The local Ethics Committee (Comité de Protection des Personnes, Rennes, France) approved the study (5 February 2009) and waived informed consent, as each plasma sample required for the study was drawn from a routine blood sample taken for biochemistry.
The patients (6 males and 3 females) were aged 59-82 years. Median body weight was 75 kg (range 48 -85 kg). The Acute Physiology and Chronic Health Evaluation II, the Simplified Acute Physiology and the Sequential Organ Failure Assessment scores ranged from 11 to 28 (median ¼15), from 36 to 55 (median¼ 47) and from 1 to 12 (median¼ 4), respectively. Four patients needed catecholamine, and one died. The bacteria recovered from the peritoneal fluids were Escherichia coli (n¼ 4), Enterococcus faecalis (n¼ 1), anaerobes (n¼ 2) and other Enterobacteriaceae (n¼ 3). We compared ertapenem concentrations with the MIC breakpoints for susceptibility testing suggested by the French Society for Microbiology [Enterobacteriaceae: susceptible ≤0.5 mg/L and resistant .1 mg/L; anaerobes: susceptible ≤1 mg/L and resistant .1 mg/L (www.sfm-microbiologie.org/)].
The patients received 1 g/day of ertapenem by intravenous infusion over a 30 min period. Plasma and peritoneal samples were obtained over the first 3 days of treatment just before the next ertapenem infusion [trough concentration (C min )]. Additionally, when it was possible, plasma samples were recovered 12 h post-administration. Simultaneously, fresh peritoneal fluid (,1 h) was drained by a vacuum suction system using a Redon catheter or latex drainage tube. Ertapenem concentrations were obtained by liquid chromatography-tandem mass spectrometry. This method is accurate and reproducible, allowing measurement of ertapenem in a range of concentrations from 0.5 to 125 mg/L.
Total ertapenem concentrations in plasma and peritoneal samples from days 1 -3 are shown in Table 1 . Data are missing for some patients because biochemistry was not performed, and/or peritoneal fluid was insufficient for analysis and/or surgical drainage was removed. There was high plasma and peritoneal inter-patient variability between ertapenem concentrations. At 24 h, 3/9 and 2/9 patients had plasma and peritoneal C min ≤0.5 mg/L, and 5/9 and 5/9 had plasma and peritoneal concentrations ≤1 mg/L, respectively. At 48 and 72 h, the results were quite similar for plasma and peritoneal concentrations. The median ratio of peritoneal/plasma ertapenem concentration was 121% (range 24% -255%).
A dose of 1 g/day administered to patients suffering from severe intra-abdominal infection achieved highly variable plasma and peritoneal concentrations of ertapenem, which were frequently below the susceptibility breakpoint for Enterobacteriaceae (,1 mg/L). This suggests that the recommended dosage is not sufficient for this situation.
As ertapenem is a b-lactam, the time above MIC is a key determinant of its activity. 4 In the ICU, a time of 100% above the MIC has been advocated with a C min /MIC of .5 in order to prevent resistance. 6 Few studies have evaluated the pharmacokinetic profile of ertapenem in critically ill patients. 7, 8 Low plasma concentrations of unbound ertapenem were reported in the study by Brink et al. 7 in eight patients with severe sepsis of various origins. The unbound ertapenem plasma concentrations did not exceed the breakpoint of 2 mg/L for Enterobacteriaceae for .40% of the 24 h dosing time in 50% of their patients. In 17 patients who had ventilator-associated pneumonia treated with ertapenem at 1 g/day, Burkhardt et al. 8 reported a high mean unbound fraction (55+19%) compared with healthy volunteers, which was associated with low free concentrations Corresponds to the minimal concentration just before 1 g of ertapenem was infused.
Research letters (0.87+0.43 and 0.24+0.43 mg/L at 12 h and 24 h, respectively). The concentration at the site of action is also a key determinant in the activity of an antimicrobial agent. Arrigucci et al. 9 have shown that peritoneal concentrations at 3 h after a 1 g intravenous infusion of ertapenem in scheduled surgery patients were 83% of the plasma concentration. In our study, the ability to assay the unbound fraction was limited because of the low total plasma and peritoneal concentrations and the high proteinbound level of this antimicrobial agent. Even if the free fraction exceeded 50%, the C min of free ertapenem would not exceed the breakpoint in these patients.
In most of our patients, total ertapenem plasma and peritoneal concentrations did not reach the target recommended for critically ill patients. 6 At 12 h after infusion, concentrations in peritoneal fluid were above the breakpoint for ertapenem susceptibility against Enterobacteriaceae and anaerobes, but at 24 h, concentrations were frequently below these thresholds. We found good peritoneal ertapenem diffusion, with concentrations equivalent to those measured in plasma, but they remained insufficient with regards to the breakpoints for susceptibility against causative bacteria. Despite the low total-plasma and peritoneal concentrations, a lack of efficacy to cure our patients could not be concluded, but the impact of such findings on clinical outcomes and the risk of selecting multiresistant bacteria are of concern. 4 In conclusion, at a fixed dose of 1 g/day, total plasma and peritoneal C min of ertapenem in patients who have severe secondary peritonitis were low with regards to breakpoint susceptibilities of this antimicrobial agent for the main bacterial types recovered in these infections. These findings suggest that dosing ertapenem at 1 g twice daily would be more suitable.
